Pune s Serum Institute of India applies for permission to start trials of Covovax vaccine The company is aiming to launch the vaccine being produced in collaboration with American vaccine development company Novavax by June 2021, SII CEO Adar Poonawalla said Representational image. PTI
Pune: Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said his company has applied to start the trials of another COVID-19 vaccine and that it hopes to launch it by June 2021.
The city-based firm has already produced Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Centre has purchased 11 million doses of Covishield vaccine for the ongoing inoculation drive.
The subject expert committee (SEC) has given the go-ahead to a clutch of firms, including Dr Reddy’s Laboratories (DRL) and Zuventus Healthcare, to conduct clinical trials on repurposed drugs for Covid-19. Mumbai’s Zuventus and Hyderabad’s DRL have got the nod to conduct Phase 3 clinical trials of Aviptadil injectable formulation. Aviptadil a vasoactive intestinal polypetide used to treat erectile dysfunction has been found to be useful in treating respiratory distress in Covid-19 patients. The US Food and Drug Administration has allowed emergency-use of the drug for treating Covid-19 patients. NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.
Kuwait Amir sends condolence cables to Iraqi top officials kuwaittimes.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuwaittimes.net Daily Mail and Mail on Sunday newspapers.
Urging the country's youth to draw inspiration from Team India's historic test cricket victory at Australia's Gabba, clinched with less experienced players, Prime Minister Narendra Modi said India must fight back challenges with the same spirit.